MDSpire - Takeaway
From the Journals

Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

Extended-release anesthetic did not significantly improve postoperative pain, raising questions about its routine use in dental surgery.

Share

  • 1

    Liposomal bupivacaine shows limited clinical benefit for third molar extraction pain management.

  • 2

    No significant difference in postoperative pain intensity compared to controls.

  • 3

    Statistically significant reduction in opioid use (-1.20 MME).

  • 4

    Need for further research emphasized due to mixed results.

  • 5

    Investigators advise caution before routine use based on limited efficacy.

Original Source(s)

Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

  • by Olivia Anderson

  • March 25, 2026

Related Content

Q&A: What are your ethical obligations if another dentist dies before completing treatment?

A recent news report described financial challenges faced by patients who had prepaid for treatment before their dentist unexpectedly died.

Lobby Day 2026 delivers strong impact

Approximately 500 dentists and dental students gathered in Washington, D.C., for Lobby Day 2026.

ADA adds mental health, GLP-1 questions to health history forms

The updated forms became available for purchase through the ADA Store on March 24.